SYDNEY, March 13, 2024 /PRNewswire/ -- Kazia Therapeutics
Limited (NASDAQ: KZIA), a biotechnology company specialising in
oncology, is pleased to announce the presentation of new data for
both its pipeline molecules, paxalisib and EVT801, at the upcoming
Annual Meeting of the American Association of Cancer Research
(AACR) in San Diego, California,
from 5-10 April 2024.
There will be three presentations in total at AACR, including
data from the phase 1 study of EVT801 in advanced solid cancers.
The data being presented will outline initial clinical data from
the phase 1 study and provides support and direction for the next
stage of the study.
In addition, data will be presented on the results of the
combination therapy of paxalisib and gemcitabine for patients with
relapsed/recurrent atypical teratoid/rhabdoid tumors AT/RT. Based
on these findings, the Pacific Pediatric Neuro-Oncology Consortium
(PNOC) is planning to include this therapy in its next AT/RT
international clinical trial.
Summary of Abstracts
Session PO.CL01.15 - Early Detection Biomarkers 1
April 7, 2024 – 1:30pm-5:00pm
Abstract 1059 / 7: Biomarkers analysis on samples from patients
in EVT801 clinical trial: Patient characterization and
immunomonitoring
L. Davenne, M. Fitzgerald, P.-B. Ancey, O.
Delpuech, C. Poussereau-Pomié, M. Esquerre, M. R. Paillasse, M.
Mandron, P. Rochaix, M. Ayyoub, C. Scarlata, C. Caux, P. Cassier,
C. Gomez-Roca, J.-P. Delord, J. Friend, P. Fons
Evotec International GmbH, Toulouse,
France, Kazia Therapeutics, Sydney, Australia, Institut Universitaire du
Cancer Toulouse-Oncopole, Toulouse,
France, Centre Léon Bérard, Lyon,
France
Session PO.CTP01.01 - Phase I Clinical Trials in Progress 1
April 8, 2024 – 9:00am-12:30pm
Abstract CT088 / 15: EVT801, a novel selective VEGFR-3 inhibitor
targeting tumor angiogenesis, is pursuing dose escalation stage of
phase I first-in-human study
C. Gomez-Roca, P. Cassier, M. Fitzgerald, L. Davenne, C.
Costantin, P. Rochaix, J.-P. Delord, J. Friend, A. Nizzardo, A.
Tagliavini, M. Pergher, P. Fons, M. Mandron
Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France, Centre Léon Bérard,
Lyon, France, Kazia Therapeutics,
Sydney, Australia, Evotec
International GmbH, Toulouse,
France, Evotec International GmbH, Verona, Italy
Session MS.CL08.01 - Novel Approaches for Targeted Therapies
April 9, 2024 – 2:50pm-3:05pm
Abstract 6565 - Improving survival of atypical teratoid/rhabdoid
tumor orthotopic xenografts through the combination of PI3K
inhibitor paxalisib and nucleoside analog gemcitabine
T. Findlay, K. Malebranche, A. Geethadevi, C. Eberhart, J.
Rubens, E. Raabe
Johns Hopkins University School of
Medicine, Baltimore, MD
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused
drug development company, based in Sydney, Australia.
Our lead program is paxalisib, an investigational
brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which
is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the
subject of ten clinical trials in this disease. A completed Phase 2
study in glioblastoma reported early signals of clinical activity
in 2021, and a pivotal study in glioblastoma, GBM AGILE, is
ongoing, with final data expected in 1H2024. Other clinical trials
are ongoing in brain metastases, diffuse midline gliomas, and
primary CNS lymphoma, with several of these having reported
encouraging interim data.
Paxalisib was granted Orphan Drug Designation for glioblastoma
by the FDA in February 2018, and FTD
for glioblastoma by the FDA in August
2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain
metastases harboring PI3K pathway mutations in combination with
radiation therapy. In addition, paxalisib was granted Rare
Pediatric Disease Designation and Orphan Drug Designation by the
FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid
tumours in June 2022 and July 2022, respectively.
Kazia is also developing EVT801, a small-molecule inhibitor of
VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided
evidence of synergy with immuno-oncology agents. A Phase I study is
ongoing and preliminary data is anticipated in CY2024.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
Forward-Looking Statements
This announcement may contain forward-looking statements, which
can generally be identified as such by the use of words such as
"may," "will," "estimate," "future," "forward," "anticipate," or
other similar words. Any statement describing Kazia's future plans,
strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are
also forward-looking statements, including, but not limited to,
statements regarding: the timing for results and data related to
Kazia's clinical and preclinical trials and investigator-initiated
trials of Kazia's product candidates, and Kazia's strategy and
plans with respect to its programs, including paxalisib and EVT801.
Such statements are based on Kazia's current expectations and
projections about future events and future trends affecting its
business and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those
anticipated in the forward-looking statements, including risks and
uncertainties: associated with clinical and preclinical trials and
product development, related to regulatory approvals, and related
to the impact of global economic conditions. These and other risks
and uncertainties are described more fully in Kazia's Annual
Report, filed on form 20-F with the United States Securities and
Exchange Commission (SEC), and in subsequent filings with the SEC.
Kazia undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required under applicable
law. You should not place undue reliance on these forward-looking
statements, which apply only as of the date of this
announcement.
This announcement was authorized for release by Dr John Friend, CEO.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-announces-presentation-of-new-data-at-aacr-annual-meeting-302087642.html
SOURCE Kazia Therapeutics Limited
